Nahrungsmittelallergien und -unverträglichkeiten

Literaturverzeichnis:

  1. Wang J, Sampson HA (2011) Food allergy. J clin Invest. 121: 827-835
  2. Raithel M. Hahn EG, Baenkler HW. Klinik und Diagnostik von Nahrungsmittelallergien (Gastrointes-tinal vermittelte Allergien Grad I – IV). English: Gastrointestinal allergies. Dtsch Ärzteblatt 2002; 99: A 780 – 786 [Heft 12]
  3. Branum AM, Lukacs SL (2009) Food allergy among children in the United States. Pediatrics 124: 1549-1555
  4. Herold G und Mitarbeiter (Hrsg). Nahrungsmittelallergie. In Innere Medizin 2008; 434 – 437
  5. Werfel T, Erdmann S, Fuchs T, Henzgen M, Kleine-Tebbe J, Lepp U, Niggemann B, Raithel M, Reese I, Saloga J, Vieths S, Zuberbier T. Approach to suspected food allergy in atopic dermatitis. Guideline of the Task Force on Food Allergy of the German Society of Allergology and Clinical Immunology (DGAKI) and the Medical Association of German Allergologists (ÄDA) and the German Society of Pediatric Allergology (GPA). J Dtsch Derm Ges 2009; 7(3): 265 – 271
  6. Raithel M, Weidenhiller M, Abel R, Baenkler HW, Hahn EG. Colorectal mucosal histamine release by mucosa oxygenation in comparison with other established clinical tests in patients with gastrointesti-nally mediated allergy (GMA). W J Gastroenterol 2006 Aug 7; 12(29): 4699 – 46705
  7. Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA et al. Guidelines for the Diagno-sis and Management of food allergy in the United States: Summary of the NIAID-Sponsored expert panel report. J Allergy Clin Immunol 2010; 126(6): S1 – S58
  8. Furlong TJ, DeSimone J, Sicherer S. Peanut and tree nut allergic reactions in restaurants and other food establishments. J Allergy Clin Immunol 2001;108:867-870
  9. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to food. J Al-lergy Clin Immunol 2001;107:191-193
  10. Host A, Halken S. Hypoallergenic formulas: when, to whom and how long: after 15 years we know the right indication. Allergy 2004; 59 suppl 78: 45-52
  11. Niggemann B, Binder C, Dupont C, Hadji S, Arvola T, Isolauri E. Prospective, controlled, multi-center study on the effect of an amino-acid based formula in infants with cow’s milk aller-gy/intolerance and atopic dermatitis. Pediatr Allergy Immunol 2001; 12: 78 – 82
  12. Schwab D, Raithel M, Hahn EG. Enterale Ernährungstherapie bei Morbus Crohn. Z Gastroenterol 1998; 36:983-995
  13. Rosenfeldt V, Benfeldt V, Valerius NH, Paerregaard A, Michaelsen KF. Effect of probiotics on gas-trointestinal symptoms and small intestinal permeability in children with atopic dermititis. J Pedi-atr 2004; 145:612-616
  14. Majamaa H, Isolauri E. Probiotics: a novel approach in management of food allergy. J Allergy Clin Immunol 1997; 99: 179-185
  15. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of E. coli Nissle 1917 involve ZO-2 and PKC PKCzeta redistribu-tion resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007; 9(3): 804-816
  16. Collins-Williams C. The role of pharmacologic agents in the prevention or treatment of allergic food disorders. Ann Allergy 1986; 57: 53 – 60
  17. Raithel M. Durchfälle und weicher Stuhl. In: Jarisch R et al. Histamin – Intoleranz. Thieme Verlag Stuttgart – New York, 2. Auflage 2004: 77 – 111
  18. Ortolani C, Pastorello E, Zanussi C. Prophylaxis of adverse reactions to foods: A double-blind study of oral sodium cromoglycate for the prophylaxis of adverse reactions to foods and additives. Ann Allergy 1983; 50: 105 – 109
  19. Raithel M, Winterkamp S, Weidenhiller M, Müller S, Hahn EG. Combination therapy using fexofenadine, disodium cromoglycate, and a hypoallergenic amino acid – based formula induced remission in a patient with steroid – dependent, chronically active ulcerative colitis. Int J Colorectal Dis 2007; 22(7): 833 – 839
  20. Raithel M. Therapie allergischer Erkrankungen des Magen – Darmtraktes: Gastrointestinal vermit-telte Allergien – Nahrungsmittelallergie. In: Merk H, Schmutzler W: Antiallergika und antiallergi-sche Therapie. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart 2003; 204 – 222
  21. Paolieri F, Battifora M, Riccio M, Bertolini C, Cutolo M, Bloom M, Ciprandi G, Canoncia GW, Bagnasco M. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human conti-nuous cell lines. Ann Allergy Asthma Immunol 1998; 81: 601 – 607.
  22. Moneret Vautrin DA, Sainte-Laudy J, Kanny G. Ulcerative colitis possibly due to hypersensitivity to wheat and egg. Allergy 2001; 56: 458 – 459
  23. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007; 120: 979-981
  24. Gerhard J Molderings, Martin Raithel, Felix Kratz, Marc Azemar, Britta Haenisch, Sabrina Harzer, Jürgen Homann. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Internal Med 2011; 50: 611 – 615
  25. Bellanti JA: Prevention of food allergies. Annals of Allergy 1984; 53: 683-91
  26. Kalliomaki M, Kirjarainen P, Eerola E, Kero P, Salinen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129-134
  27. Reinhart Jarisch, Knut Brockow, Manfred Götz, Wolfgang Hemmer, Christian Layritz, Verena Niederberger, Martin Raithel, Felix Wantke. Histaminintoleranz – Histamin und Seekrankheit. Thieme Verlag Stuttgart – New York, 3. Auflage 2013: 92 – 93
  28. Raithel M. Gastrointestinal vermittelte Allergien und Histaminintoleranz. In: Jarisch R et al. Histaminintoleranz – Histamin und Seekrankheit. Thieme Verlag Stuttgart – New York, 3. Auflage 2013: 86 – 102
  29. Zar S, Kumar D, Benson MJ. Review article: Food hypersensitivity and irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 439 – 449
  30. Lillestol K, Helgeland L, Lied GA. Florvaag E, Valeur J, Lind R, Berstad A. Indications of “atopic bowel” in patients with self-reported food hypersensitivity. Aliment Pharmacol 2010; 31: 1112-1122.
  31. Klooker T et al. Gut 2010; 59: 1213-1221
  32. Niec AM, Frankum B, Talley NJ. Are adverse food reactions linked to irritable bowel syndrome ? Am J Gastroenterol 1998; 93: 2184 – 2190
  33. De Maeyer N, Kochuyt AM, Van Moerkercke W, Hiele M. Montekulast as a treatment modality for eosinophilic gastroenteritis. Acta Gastroenterol Belgium 2011 Dec; 74 (4): 570-575
  34. Selva Kumar C, Das RR, Balakrishnan CD, Balagurunathan K, Chaudhuri K. Malabsorption syndrome and leukotriene inhibitor. J Trop Pediatrics 2001 April; 57 (2) 135 – 137
  35. Dieter Steinhilber, Bettina Hofmann, Institute of Pharmaceutical Chemistry, Goethe University Frankfurt. Recent Advances in the Search for Novel 5-Lipoxygenase Inhibitors. 2013 Nordic Pharmacological Society, John Wiley & Sons Ltd
  36. C Pergola, J Gerstmeier et al. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP). British Journal of Pharmacology 2014. DOI: 10.1111/bph.12625
  37. Raithel M. Mastozytose und Mastzellüberaktivitätssyndrom In: Jarisch R et al. Histaminintoleranz – Histamin und Seekrankheit. Thieme Verlag Stuttgart – New York, 3. Auflage 2013: 105 – 113
  38. Raithel M, Dormann H, Schwab D, Winterkamp S, Weidenhiller M, Fischer B, Hahn EG, Schneider Th. Immunoglobulin E production in chronic pancreatitis. Eur J Gastroenterol Hepatol 2003; 15: 1 – 7
  39. D F Finn, J J Walsh. Twenty-first century mast cell stabilizers. British Journal of Pharmacology (2013) 170: 23–37
  40. Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, et al. (2012) Quercetin Is More Effective than Cromolyn in Blocking Human Mast Cell Cytokine Release and Inhibits Contact Dermatitis and Photosensitivity in Humans. PLoS ONE 7(3): e33805. doi:10.1371/journal.pone.0033805
  41. Omid Sascha Yousefi, Thomas Wilhelm, Karin Maschke-Neuß, Marcel Kuhny, Christian Martin, Gerhard J Molderings, Felix Kratz, Bernd Hildenbrand and Michael Huber. The 1,4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions. Cell Communication and Signaling 2013, 11:13
  42. AWMF-Leitlinien-Register Nr. 061/025, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
  43. Weidenhiller M et al. Histaminintoleranz-Syndrom (HIS): Vielfalt der Mechanismen von physiologischer, pathophysiologischer und toxischer Wirkung und deren Unterscheidung. Z Gastroenterologie 2012; 50: 1302–1309
  44. Britta Haenisch, Markus M. Nöthen, Gerhard J. Molderings, Institute of Human Genetics, University Hospital of Bonn, Germany. Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology 2012 Blackwell Publishing Ltd, Immunology, 137, 197–205
  45. Stein J, Kist M, Raithel M: Erkrankungen durch Nahrungsmittel. Wissenschaftliche Verlagsgesellschaft Stuttgart 2011
  46. Vatn MH et al. Adverse Reaction to Food: Assessment by double-blind placebo-controlled food challenge and clinical, psychosomatic and immunologic analysis. Digestion 1995; 56: 421–428
  47. Born P et al. Carbohydrate malabsorption in clinical routine: a prospective observational study. Hepatogastroenterology 2006; 71: 673–677
  48. Lomer MCE, Parkes GC, Sanderson JD. Review article: lactose intolerance in clinical practice – myths and realities. Aliment Pharmacol 2008; 27: 93–103
  49. Fernandez-Banares F et al. Sugar malabsorption in functional abdominal bloating: A pilot study on the long-term effect of dietary treatment. Clinical Nutrition 2006; 25: 824–831
  50. Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I, Bondar O, Dyer RB, Lamsam J, Zinsmeister AR. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012; 10: 1009–1019

<< Vorherige Seite


Print Friendly, PDF & Email

VAEM Frontend vers. 0.1

47 database queries in 0,502